SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Prelude Therapeutics Q3 2026 net loss narrows 36% to $12.54 million

Prelude Therapeutics Q3 2026 net loss narrows 36% to $12.54 million Prelude Therapeutics’ third

PRLD

Related stories